الفهرس 
Acknowledgement
MENORRHAGIA IN IUCDS`USERSOnly 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
The aim of the study was to evaluate the efficacy of Ca dobesilate and tranexmic acid in women with IUCD associated heavy menstrual blood loss. The study was randomized, open-label, controlled trial. Women who were using IUD (TCu-380) with complaints of heavy menstrual blood loss were randomly divided into two equal groups (Ca Dobesilate and Tranexamic Acid). The pictorial blood assessment chart (PBAC) was used to measure blood loss in 1st, 2nd and 3rd visits from complaining bleeding. Side effects were also recorded The study patients were subdivided into 2 groups: group 1 received Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle for 5 days for 3 cycles. group 2 received Ca Dobesilate oral tablets 500 mg \ three times daily with the onset of the first day of menstrual cycle for 5 days for 3 cycles. The amount of menstrual flow was assessed by the PBAC. Patient satisfaction was measured by likert scale. Both groups were comparable in their baseline demographic, menstrual, obstetric and insertion characteristics. women in both groups reported subjective and objective improvement in their menstrual flow. The improvement was progressive from the first to the third visit in both groups. Those who received Tranexamic Acid had significantly more decrease in menstrual blood loss compared to women who received Calcium Dobesilate in all the three follow up visits. There was 14% of the tranexamic acid and 25% in the calcium dobesilate group needed additional treatment . The main side effect of tranexamic acid was GIT upset 28%. The main side effect of calcium dobesilate was headache 17%. No one in tranexamic acid group requested to use another method versus one client in calcium dobesilate group. At the end of the three cycles of treatment, 61% were either neutral, satisfied or very satisfied with tranexamic acid versus 53% in Calcium dobesilate. Both Tranexamic Acid and Calcium Dobesilate are efficacious on reducing the menstrual blood loss associated with IUCD users. Tranexamic acid more efficacious than calcium dobesilate in reducing IUCD associated menorrhagia. More side effects with tranexamic acid were recorded but not affect on continuation usage of IUCD. More additional treatment was needed in calcium dobesilate group than Tranexamic acid group. More satisfaction with tranexamic acid group were recorded compared with calcium dobesilate. Both Tranexamic Acid and Calcium Dobesilate helped continuation of IUCD use but only one client opted for discontinuation in calcium dobesilate users. Depending on reduction of PBAC score as a measurement of reduction in MBL , This study showed that Tranexamix Acid was more effective in reducing menstrual blood loss than Calcium Dobesilate in women using IUCD. Women using Tranexamix Acid were very satisfied for this drug but fewer number of women using Calcium Dobesilate were satisfied for this treatment.